AnaptysBio Files 8-K
Ticker: ANAB · Form: 8-K · Filed: Sep 29, 2025 · CIK: 1370053
| Field | Detail |
|---|---|
| Company | Anaptysbio, Inc (ANAB) |
| Form Type | 8-K |
| Filed Date | Sep 29, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, SEC Filing, Disclosure
Related Tickers: ANAB
TL;DR
ANAB filed an 8-K on 9/29/25 - check for material updates.
AI Summary
AnaptysBio, Inc. filed an 8-K on September 29, 2025, reporting on events that occurred on the same date. The filing includes information related to Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. Specific financial details or material events are not detailed in the provided text excerpt.
Why It Matters
This filing indicates AnaptysBio is making a regulatory disclosure or reporting other significant events to the SEC, which could impact investors' understanding of the company's current status.
Risk Assessment
Risk Level: low — The provided text is a standard SEC filing notification and does not contain specific financial or operational risks.
Key Players & Entities
- ANAPTYSBIO, INC (company) — Registrant
- September 29, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 10770 Wateridge Circle, Suite 210, San Diego, CA 92121 (address) — Principal Executive Offices
- 858-362-6295 (phone_number) — Registrant's Telephone Number
FAQ
What specific events are being disclosed under Regulation FD?
The provided text does not specify the details of the Regulation FD disclosure.
What are the 'Other Events' being reported by AnaptysBio?
The filing mentions 'Other Events' but does not provide specifics in the excerpt.
What financial statements or exhibits are included in this filing?
The filing indicates 'Financial Statements and Exhibits' are included, but the content is not detailed in the provided text.
When was AnaptysBio, Inc. incorporated?
AnaptysBio, Inc. was incorporated in Delaware.
What is the principal executive office address for AnaptysBio, Inc.?
The principal executive office is located at 10770 Wateridge Circle, Suite 210, San Diego, CA 92121.
Filing Stats: 612 words · 2 min read · ~2 pages · Grade level 9.8 · Accepted 2025-09-29 16:29:55
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share ANAB The Nasdaq Stock Marke
Filing Documents
- anab-20250929.htm (8-K) — 25KB
- strategicseparationtomax.htm (EX-99.1) — 19KB
- anaptysannouncesintentto.htm (EX-99.2) — 15KB
- anaptysannouncesintentto001.jpg (GRAPHIC) — 257KB
- anaptysannouncesintentto002.jpg (GRAPHIC) — 247KB
- anaptysannouncesintentto003.jpg (GRAPHIC) — 289KB
- anaptysannouncesintentto004.jpg (GRAPHIC) — 91KB
- strategicseparationtomax001.jpg (GRAPHIC) — 90KB
- strategicseparationtomax002.jpg (GRAPHIC) — 351KB
- strategicseparationtomax003.jpg (GRAPHIC) — 138KB
- strategicseparationtomax004.jpg (GRAPHIC) — 174KB
- strategicseparationtomax005.jpg (GRAPHIC) — 177KB
- strategicseparationtomax006.jpg (GRAPHIC) — 153KB
- strategicseparationtomax007.jpg (GRAPHIC) — 135KB
- strategicseparationtomax008.jpg (GRAPHIC) — 183KB
- strategicseparationtomax009.jpg (GRAPHIC) — 132KB
- strategicseparationtomax010.jpg (GRAPHIC) — 95KB
- strategicseparationtomax011.jpg (GRAPHIC) — 214KB
- strategicseparationtomax012.jpg (GRAPHIC) — 193KB
- strategicseparationtomax013.jpg (GRAPHIC) — 160KB
- 0001370053-25-000081.txt ( ) — 4471KB
- anab-20250929.xsd (EX-101.SCH) — 2KB
- anab-20250929_def.xml (EX-101.DEF) — 9KB
- anab-20250929_lab.xml (EX-101.LAB) — 29KB
- anab-20250929_pre.xml (EX-101.PRE) — 20KB
- anab-20250929_htm.xml (XML) — 3KB
01. Regulation FD
Item 7.01. Regulation FD. On September 29, 2025, AnaptysBio, Inc. ("AnaptysBio") will host a conference call to discuss the potential separation of its business referred to and described under Item 8.01 below, and use a slide presentation in conjunction with the call. A copy of the presentation is filed herewith as Exhibit 99.1, and incorporated herein by reference. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.
01. Other Events
Item 8.01. Other Events. On September 29, 2025, AnaptysBio issued a press release (the "Press Release") announcing that its Board of Directors approved plans to explore separating its business into two independent, publicly traded companies and that the separation is expected to occur by the end of 2026. A copy of the press release is attached as Exhibit 99.2 to this Current Report on Form 8-K.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Title or Description 99.1 AnaptysBio, Inc. Investor Presentation, dated September 29, 2025. 99.2 Press release issued by AnaptysBio, Inc., dated September 29, 2025. 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. AnaptysBio, Inc. Date: September 29, 2025 By: /s/Dennis Mulroy Name: Dennis Mulroy Title: Chief Financial Officer